Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

The Swan Medical ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 7.5% 7.5%   Bankruptcy risk   15.6% 13.2% 9.7% 10.2% 9.5% 5.6% 18.2% 18.2%   Credit score (0-100)   13 18 25 23 25 40 8 8   Credit rating   BB BB BB BB BB BBB B B   Credit limit (kDKK)   -0.0 -0.0 -0.0 -0.0 -0.0 -0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   -166 87.2 138 135 292 901 0.0 0.0   EBITDA   -224 -95.8 -31.2 -122 -251 415 0.0 0.0   EBIT   -266 -196 -158 -301 -430 278 0.0 0.0   Pre-tax profit (PTP)   -275.9 -217.9 -185.3 -302.2 -431.1 276.9 0.0 0.0   Net earnings   -215.2 -170.1 -144.6 -235.7 -336.3 215.8 0.0 0.0   Pre-tax profit without non-rec. items   -276 -218 -185 -302 -431 277 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   206 483 606 449 270 362 0.0 0.0   Shareholders equity total   -165 -335 -480 -716 -1,052 -836 -886 -886   Interest-bearing liabilities   409 794 1,075 1,433 1,458 1,398 886 886   Balance sheet total (assets)   316 688 857 803 757 883 0.0 0.0   Net Debt   369 717 1,014 1,353 1,380 1,270 886 886     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   -166 87.2 138 135 292 901 0.0 0.0   Gross profit growth   0.0% 0.0% 58.2% -2.3% 116.7% 208.7% -100.0% 0.0%   Employees   1 1 1 2 4 3 0 0   Employee growth %   0.0% 0.0% 0.0% 100.0% 100.0% -25.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   316 688 857 803 757 883 0 0   Balance sheet change%   0.0% 117.8% 24.5% -6.3% -5.8% 16.7% -100.0% 0.0%   Added value   -224.4 -95.8 -31.2 -122.4 -251.8 415.0 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   164 176 -3 -336 -359 -45 -362 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -1.0 -2.0 -3.0 -4.0 -5.0 1.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   160.9% -224.9% -114.6% -223.4% -147.4% 30.8% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -55.4% -26.0% -13.4% -21.1% -25.9% 15.7% 0.0% 0.0%   ROI %   -65.2% -32.6% -16.9% -24.0% -29.8% 19.4% 0.0% 0.0%   ROE %   -68.1% -33.9% -18.7% -28.4% -43.1% 26.3% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   -34.3% -32.8% -35.9% -47.1% -58.2% -48.6% -100.0% -100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -164.2% -748.3% -3,247.7% -1,104.9% -549.7% 306.1% 0.0% 0.0%   Gearing %   -247.4% -236.8% -224.1% -200.3% -138.6% -167.2% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   4.6% 3.6% 2.9% 0.1% 0.0% 0.0% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   1.4 0.9 0.9 4.0 1.4 1.6 0.0 0.0   Current Ratio   1.4 0.9 0.9 4.0 1.4 1.6 0.0 0.0   Cash and cash equivalent   40.1 77.4 60.9 80.5 78.2 127.4 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   28.2 -33.4 -19.9 259.4 127.1 190.4 -443.0 -443.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   -224 -96 -31 -61 -63 138 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   -224 -96 -31 -61 -63 138 0 0   EBIT / employee   -266 -196 -158 -151 -108 93 0 0   Net earnings / employee   -215 -170 -145 -118 -84 72 0 0